Nontuberculous mycobacteria (NTM) are opportunistic pathogens capable of causing pulmonary disease [1]. Antimicrobial regimens are complex and lengthy, requiring multidrug treatment for 18–24 months [1]. Drug choices are limited due to NTM resistance profiles and interactions with other medications [2]. These medications can be associated with adverse events including prolonged corrected QT (QTc) intervals (macrolides, fluroquinolones and clofazimine), hearing loss and ototoxicity (macrolides and aminoglycosides) [3, 4].

中文翻译：

---

非结核分枝杆菌治疗方案中不良电生理和听力变化的发生率

非结核分枝杆菌 (NTM) 是能够引起肺部疾病的机会性病原体 [1]。抗菌方案复杂而漫长，需要 18-24 个月的多种药物治疗 [1]。由于 NTM 耐药性和与其他药物的相互作用，药物选择受到限制 [2]。这些药物可能与不良事件相关，包括校正 QT (QTc) 间期延长（大环内酯类、氟喹诺酮类和氯法齐明）、听力损失和耳毒性（大环内酯类和氨基糖苷类）[3, 4]。